Stirred batch crystallization of a therapeutic antibody fragment

Journal of Biotechnology

Volumn 166, Issue 4, 2013, Pages 206-211

  Hebel, Dirk ^a   Huber, Sabine ^a   Stanislawski, Bernd ^b   Hekmat, Dariusch ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b MERCK KGAA   (Germany)

Author keywords

Antibody fragment; Protein crystallization; Scale up; Stirred tank

Indexed keywords

ANTIBODY FRAGMENT; CRYSTAL SIZE DISTRIBUTIONS; CRYSTALLIZATION CONDITIONS; CRYSTALLIZATION PROCESS; PROTEIN CRYSTALLIZATION; QUANTITATIVE MEASUREMENT; SCALE-UP; STIRRED TANK;

CRYSTALLIZERS; DRUG DELIVERY; EXPERIMENTS; OPTIMIZATION; TANKS (CONTAINERS); VAPORS;

ANTIBODIES;

AMMONIUM SULFATE; IMMUNOGLOBULIN F(AB) FRAGMENT;

ARTICLE; CRYSTAL STRUCTURE; CRYSTALLIZATION; KINETICS; PRIORITY JOURNAL; VAPOR;

ANTIBODY FRAGMENT; PROTEIN CRYSTALLIZATION; SCALE-UP; STIRRED TANK;

AMMONIUM SULFATE; CHEMICAL PRECIPITATION; CRYSTALLIZATION; IMMUNOGLOBULIN FAB FRAGMENTS; MOTION; OSMOLAR CONCENTRATION; PARTICLE SIZE; SUSPENSIONS; TIME FACTORS;

EID: 84880354946     PISSN: 01681656     EISSN: 18734863     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2013.05.010     Document Type: Article

References (34)

1. Andya J.D., Hsu C.C., Shire S.J. Mechanisms of aggregate formation and carbohydrate excipient stabilization of lyophilized humanized monoclonal antibody formulations. AAPS PharmSci 2003, 5:E10.
2. Asenjo J.A., Andrews B.A. Aqueous two-phase systems for protein separation: phase separation and applications. Journal of Chromatography A 2012, 1238:1-10.
3. Basu S.K., Govardhan C.P., Jung C.W., Margolin A.L. Protein crystals for the delivery of biopharmaceuticals. Expert Opinion on Biological Therapy 2004, 4:301-317.
4. Elkordy A.A., Forbes R.T., Barry B.W. Integrity of crystalline lysozyme exceeds that of a spray dried form. International Journal of Pharmacy 2002, 247:79-90.
5. Elkordy A.A., Forbes R.T., Barry B.W. Stability of crystallised and spray-dried lysozyme. International Journal of Pharmacy 2004, 278:209-219.
6. Franzreb M., Siemann-Herzberg M., Hobley T.J., Thomas O.R.T. Protein purification using magnetic adsorbent particles. Applied Microbiology and Biotechnology 2006, 70:505-516.
7. George A., Chian Y., Guo B., Arabshahi A., Cai Z., Wilson W.W. Second virial coefficient as predictor in protein crystal growth. Methods in Enzymology 1997, 276:100-110.
8. Giffard M., Ferté N., Ragot F., El Hajji M., Castro B., Bonneté F. Urate oxidase purification by salting-in crystallization: towards an alternative to chromatography. PLoS ONE 2011, 6:e19013.
9. Harrison R., Todd P., Rudge S., Petrides D. Bioseparations Science and Engineering 2003, Oxford University Press, New York.
10. Hebel D., Ürdingen M., Hekmat D., Weuster-Botz D. Development and scale-up of high-yield crystallization processes of lysozyme and lipase using additives. Crystal Growth and Design 2013, 10.1021/cg400212p.
11. Hekmat D., Hebel D., Schmid H., Weuster-Botz D. Crystallization of lysozyme: from vapor diffusion experiments to batch crystallization in agitated ml-scale vessels. Process Biochemistry 2007, 42:1649-1654.
12. Jacobsen C., Garside J., Hoare M. Nucleation and growth of microbial lipase crystals from clarified concentrated fermentation broths. Biotechnology and Bioengineering 1998, 57:666-675.
13. Judge R.A., Johns M.R., White E.T. Protein purification by bulk crystallization: the recovery of ovalbumin. Biotechnology and Bioengineering 1995, 48:316-323.
14. Kelley B. Very large scale monoclonal antibody purification: the case for conventional unit operations. Biotechnology Progress 2007, 23:995-1008.
15. Lee T., Vaghjiani J., Lye G., Turner M. A systematic approach to the large-scale production of protein crystals. Enzyme and Microbial Technology 2000, 26:582-592.
16. Lewus R.A., Darcy P.A., Lenhoff A.M., Sandler S.I. Interactions and phase behavior of a monoclonal antibody. Biotechnology Progress 2011, 27:280-289.
17. Li S., Schmitz K.R., Jeffrey P.D., Wiltzius J.J.W., Kussie P., Ferguson K.M. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005, 7:301-311.
18. Liu J., Yin D.-C., Guo Y.-Z., Wang X.-K., Xie S.-X., Lu Q.-Q., Liu Y.-M. Selecting temperature for protein crystallization screens using the temperature dependence of the second virial coefficient. PLoS ONE 2011, 6:e17950.
19. Low D., O'Leary R., Pujar N.S. Future of antibody purification. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2007, 848:48-63.
20. Manning M.C., Chou D.K., Murphy B.M., Payne R.W., Katayama D.S. Stability of protein pharmaceuticals: an update. Pharmaceutical Research 2010, 27:544-575.
21. Matthews T., Bean B. Development of a scaleable protein purification process using crystallization. Bioprocess International Conference and Exhibition 2006.
22. Mirro R., Voll K. Which impeller is right for your cell line?. Bioprocess International 2009, 7:52-57.
23. Pechenov S., Shenoy B., Yang M.X., Basu S.K., Margolin A.L. Injectable controlled release formulations incorporating protein crystals. Journal of Controlled Release 2004, 96:149-158.
24. Saxena A., Tripathi B.P., Kumar M., Shahi V.K. Membrane-based techniques for the separation and purification of proteins: an overview. Advances in Colloid and Interface Science 2009, 145:1-22.
25. Schlichtkrull J. Insulin crystals V: the nucleation and growth of insulin crystals. Acta Chemica Scandinavica 1957, 11:439-460.
26. Schmidt S., Havekost D., Kaiser K., Kauling J., Henzler H.-J. Crystallization for the downstream processing of proteins. Engineering in Life Sciences 2005, 5:273-276.
27. Shenoy B., Wang Y., Shan W., Margolin a.L. Stability of crystalline proteins. Biotechnology and Bioengineering 2001, 73:358-369.
28. Shukla A.A., Hubbard B., Tressel T., Guhan S., Low D. Downstream processing of monoclonal antibodies - application of platform approaches. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2007, 848:28-39.
29. Shukla A.A., Thömmes J. Recent advances in large-scale production of monoclonal antibodies and related proteins. Trends in Biotechnology 2010, 28:253-261.
30. Takakura T., Ito T., Yagi S., Notsu Y., Itakura T., Nakamura T., Inagaki K., Esaki N., Hoffman R.M., Takimoto A. High-level expression and bulk crystallization of recombinant l-methionine gamma-lyase, an anticancer agent. Applied Microbiology and Biotechnology 2006, 70:183-192.
31. Thömmes J., Etzel M. Alternatives to chromatographic separations. Biotechnology Progress 2007, 23:42-45.
32. Trilisky E., Gillespie R., Osslund T.D., Vunnum S. Crystallization and liquid-liquid phase separation of monoclonal antibodies and Fc-fusion proteins: screening results. Biotechnology Progress 2011, 27:1054-1067.
33. Yang M.X., Shenoy B., Disttler M., Patel R., McGrath M., Pechenov S., Margolin A.L. Crystalline monoclonal antibodies for subcutaneous delivery. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:6934-6939.
34. Zang Y., Kammerer B., Eisenkolb M., Lohr K., Kiefer H. Towards protein crystallization as a process step in downstream processing of therapeutic antibodies: screening and optimization at microbatch scale. PLoS ONE 2011, 6:e25282.